Mikhail N. Kosiborod, MD, Professor of Medicine, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence. In this video, he speaks about A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE). Brief Synopsis: This is a study of adults admitted to the hospital with acute heart failure. The goal of this trial is to see if beginning a drug called empagliflozin immediately after being admitted to the hospital helps persons with acute heart failure. Participants will be enrolled in the trial for approximately three months. Participants are still in the hospital at the start. Later, they visit the hospital three times and receive one phone call. Participants are randomly assigned to one of two groups. One group receives one empagliflozin pill every day. The other group chooses One placebo tablet per day. Placebo tablets resemble empagliflozin tablets but contain no medication. Empagliflozin is an SGLT-2 inhibitor, which is a type of medication. It is employed in the treatment of type 2 diabetes. During the trial, doctors look to see if participants have any more heart failure events, such as needing to go to the hospital again due to heart failure. Participants respond to questions regarding how their heart failure affects their daily lives. The outcomes are then compared between the empagliflozin and placebo groups. The participants' overall health is also checked on a regular basis by the doctors. - Heart Failure and Cardiomyopathies - 741_600c9efaa3c99

Mikhail N. Kosiborod, MD @MkosiborodMD @saintlukeskc @MidAmericaHeart #ADHF Phase III EMPULSE Study

Mikhail N. Kosiborod, MD @MkosiborodMD @saintlukeskc @MidAmericaHeart #ADHF Phase III EMPULSE Study

5 months
32 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Mikhail N. Kosiborod, MD, Professor of Medicine, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence. In this video, he speaks about A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE).

 

Brief Synopsis:

 

This is a study of adults admitted to the hospital with acute heart failure. The goal of this trial is to see if beginning a drug called empagliflozin immediately after being admitted to the hospital helps persons with acute heart failure.

 

Participants will be enrolled in the trial for approximately three months. Participants are still in the hospital at the start. Later, they visit the hospital three times and receive one phone call. Participants are randomly assigned to one of two groups. One group receives one empagliflozin pill every day. The other group chooses

 

One placebo tablet per day. Placebo tablets resemble empagliflozin tablets but contain no medication. Empagliflozin is an SGLT-2 inhibitor, which is a type of medication. It is employed in the treatment of type 2 diabetes.

 

During the trial, doctors look to see if participants have any more heart failure events, such as needing to go to the hospital again due to heart failure. Participants respond to questions regarding how their heart failure affects their daily lives. The outcomes are then compared between the empagliflozin and placebo groups. The participants' overall health is also checked on a regular basis by the doctors.

Up Next Autoplay